Christopher Smith, MD
Internal Medicine · Wellesley, MANPI 1992758528
Payments from drug & device makers
What this record shows
This record is dominated by education: $112 of the $138 with a category attached, or 81.5%. Amarin Pharma, Inc. accounts for 81.5% of it on its own, with 1 other manufacturer making up the rest.
Across 20 payments — averaging $6.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$112
- Medicomp Inc$26
Across 6 payments — averaging $905.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Idorsia Pharmaceuticals US Inc$5K
What the payments were for
- Food & beverage$2619%
- Education$11281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 19 | $112 |
| Medicomp Inc | 1 | $26 |
How this compares
$138 in reported general payments places this provider in the 65th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $119,960 |
| XareltoRivaroxaban | 36 | $36,913 |
| JardianceEmpagliflozin | 27 | $27,020 |
| JanuviaSitagliptin Phosphate | 27 | $24,939 |
| TrulicityDulaglutide | 15 | $19,343 |
| MounjaroTirzepatide | 19 | $18,986 |
| Atorvastatin Calcium | 503 | $8,488 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,800 |
| Rosuvastatin Calcium | 207 | $6,208 |
| MyrbetriqMirabegron | 12 | $6,167 |
| Qvar RedihalerBeclomethasone Dipropionate | 19 | $5,278 |
| Celecoxib | 56 | $5,129 |
| Metoprolol Succinate | 198 | $4,116 |
| Eszopiclone | 15 | $4,076 |
| Omeprazole | 206 | $3,385 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wellesley
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.